<DOC>
	<DOCNO>NCT01726582</DOCNO>
	<brief_summary>See treatment pathway http : //www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm : In clinical trial , doctor know suspect growth pancreas cancer ( adenocarcinoma ) , sample growth test ( test call molecular profiling ) . The result test use doctor recommend therapy ( chemotherapy radiation therapy ) patient receive surgery remove adenocarcinoma . When patient go surgery , adenocarcinoma remove test . The result test use guide choice therapy surgery . The chemotherapy drug radiation therapy use clinical trial already approve treatment pancreas cancer . This trial intend establish treatment best specific patient , base test result patient 's actual adenocarcinoma . In past , decision treatment patient receive base test actual adenocarcinoma . Hypothesis : Resectability rate , overall survival rate progression-free survival superior patient adenocarcinoma pancreas receive target `` personalized '' therapy , compare historical data patient receive standard therapy .</brief_summary>
	<brief_title>Pancreas Cancer : Molecular Profiling Guide Therapy Before After Surgery ( `` Personalized Medicine '' )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Enrollment/ eligibility criterion : 18 year age old Able understand provide write informed consent Diagnosis adenocarcinoma pancreas high suspicion adenocarcinoma pancreas base CT MRI finding detail `` Definition ... . '' Treatment Eligibility Criteria : Have ECOG performance status less equal 2 Have biopsyproven resectable borderline resectable adenocarcinoma pancreas Have adequate organ bone marrow function define : total leukocyte great equal 3 x1000/μL absolute neutrophil count ( ANC ) &gt; equal 1.5x 1000/μL hemoglobin &gt; equal 9 g/dL platelet &gt; equal 100 x 1000/μL creatinine clearance &gt; 60 mL/min creatinine &lt; equal 1.5 mg/dL bilirubin &lt; equal 2 mg/dL &gt; 2 decline describe protocol aspartate transaminase ( AST/SGOT ) &lt; equal to3 x ULN alanine transaminase ( ALT/SGPT ) &lt; equal 3 x ULN Female patient must post menopausal &gt; 1 year , surgically sterile , negative pregnancy test use least one form contraception 4 week prior Day 1 study , study treatment first 4 month study treatment discontinue . Male patient must surgically sterile use barrier contraception study 4 month last dose study drug . Definition Resectable Pancreatic Cancer include : No evidence extrapancreatic disease No evidence tumorarterial abutment ( celiac , SMA HA ) If tumor induce narrowing SMV , PV SMPV confluence present must &lt; 50 % diameter vessel Ca 199 &lt; 5000 , bilirubin &lt; 2 ( &gt; 2 decline describe protocol ) Definition Borderline Resectable Pancreatic Cancer include least one following : Tumor abutment &lt; equal 180 degree SMA celiac axis Tumor abutment encasement ( &gt; 180 degree ) short segment HA Tumor induce narrow SMV , PV SMPV &gt; 50 % diameter vessel . Short segment occlusion SMV , PV SMVPV suitable PV SMV , reconstruction CT MRI finding suspicious , diagnostic , metastatic disease ( base multidisciplinary assessment MCW weekly pancreatic cancer conference ) Biopsy proven N1 disease ( regional lymph node involve ) prereferral biopsy EUSguided FNA Resectable tumor CA 199 &gt; 5000 Any patient one follow exclude : Have receive chemotherapy chemoradiation within 5 year prior study enrollment Have previous history another malignancy ( cure basal squamous cell carcinoma skin cure insitu carcinoma cervix ) within 5 year study enrollment Uncontrolled comorbidities include , limited , ongoing active serious infection , symptomatic congestive heart failure , unstable angina , unstable cardiac arrhythmia , psychiatric illness , excessive obesity , situation would limit compliance study requirement ability willingly give write informed consent Known HIV , HBV , HCV infection Pregnant breastfeeding patient patient childbearing potential use contraception 4 week prior , 4 month study treatment discontinue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pancreas</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>molecular profile</keyword>
	<keyword>molecular profiling</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>pancreas cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>molecular target</keyword>
	<keyword>pancreas head</keyword>
	<keyword>pancreas neck</keyword>
	<keyword>pancreas uncinate</keyword>
	<keyword>pancreas body</keyword>
	<keyword>pancreas tail</keyword>
</DOC>